NCT05968573Completed
Persuasive Health Communication Intervention for HIV/HCV
Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV/HCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the research team will assess how well a promising, easy-to-use, one-time, minimal-training-needed, very brief persuasive health communication intervention (PHCI) increases acceptance of testing among adult ED patients who either currently, formerly or never injected drugs and initially declined HIV/HCV screening. The research team will conduct a randomized, controlled trial (RCT) at EDs within the Mount Sinai Health System to compare the efficacy of the PHCI when delivered by a video vs. an HIV/HCV counselor. Patients who initially declined HIV/HCV screening will be stratified by injection-drug use (IDU) history cohorts: (1) current/former PWIDs, (2) never/non-PWIDs. Within each IDU history cohort, the research team will randomly assign participants (1:1:1) to a PHCI delivered by: (1) a video with captions, (2) a video without captions, (3) an HIV/HCV counselor. This R01 project will be conducted at Mount Sinai affiliate hospitals EDs. For Aim 2, the research team will determine if screening acceptance is similar across IDU history cohorts. For Aim 3, the research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2000 (actual)
- First submitted
- 21 Jul 2023
- Start date
- 4 Dec 2023
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- University of South Florida
- Diseases
- HIV
- NCT number
- NCT05968573
What you commit to
- Study type: Interventional
- Participants enrolled: 2000
- From 4 Dec 2023 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV or HCV positive
- Currently enrolled in another HIV or HCV research study
- Has tested for HIV or HCV in the past 12 months
Age
- \<18 years old
Other
- Unable to speak Spanish or English
Who the study is looking for
- ≥18 years-old
- Speak English or Spanish, and able to provide informed consent for study participation
- Not HIV AND HCV infected/Antibody+ (per EHR review and patient report)
- Not already participating in a HIV or HCV study (e.g., HIV PrEP, HIV vaccine)
- Not tested for HIV OR HCV within the past 12 months (per EHR review and patient report)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.